Michelle Cespedes is an Infectious Disease physician affiliated with Icahn School of Medicine at Mount Sinai. OpenAlex indexes 31 publications with 1,056 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
7 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
53.6%Statin12.5%Atorvastatin Calcium53%Rosuvastatin Calcium47%Part D<11 patientsACE inhibitor11.8%Lisinopril65%Ramipril35%Part D<11 patients+ 6 more classes in this area
Anti-infectives
35.6%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor13%Tivicay72%Isentress28%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor12.8%Triumeq64%Descovy37%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
4.4%Proton pump inhibitor4.4%Omeprazole100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Heart Failure Risk and Events in People With HIV: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Circulation Heart Failure
2025 - Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee
Clinical Infectious Diseases
2024 - 965. Projecting the Potential Clinical and Economic Impact of HIV Prevention Resource Reallocation in Tennessee
Open Forum Infectious Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”